KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Biomarin Pharmaceutical (BMRN) Amortization - Deferred Charges (2017 - 2018)

Historic Amortization - Deferred Charges for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Q2 2018 value amounting to $1.0 million.

  • Biomarin Pharmaceutical's Amortization - Deferred Charges rose 1354.4% to $1.0 million in Q2 2018 from the same period last year, while for Jun 2018 it was $3.5 million, marking a year-over-year increase of 532.9%. This contributed to the annual value of $3.6 million for FY2018, which is 308.72% down from last year.
  • Biomarin Pharmaceutical's Amortization - Deferred Charges amounted to $1.0 million in Q2 2018, which was up 1354.4% from $886000.0 recorded in Q2 2017.
  • Biomarin Pharmaceutical's Amortization - Deferred Charges' 5-year high stood at $1.0 million during Q2 2018, with a 5-year trough of $823000.0 in Q3 2015.
  • Moreover, its 4-year median value for Amortization - Deferred Charges was $827500.0 (2014), whereas its average is $865500.0.
  • In the last 5 years, Biomarin Pharmaceutical's Amortization - Deferred Charges surged by 121428.57% in 2014 and then tumbled by 60.39% in 2015.
  • Over the past 4 years, Biomarin Pharmaceutical's Amortization - Deferred Charges (Quarter) stood at $827000.0 in 2014, then dropped by 0.48% to $823000.0 in 2015, then grew by 7.65% to $886000.0 in 2017, then increased by 13.54% to $1.0 million in 2018.
  • Its last three reported values are $1.0 million in Q2 2018, $886000.0 for Q2 2017, and $823000.0 during Q4 2015.